3 hours Cardiol Therapeutics (NASDAQ:CRDL) Rating Reiterated by HC WainwrightMarketBeat
HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Thursday.
XHC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Thursday.
X